"It Didn't Work for Me" May Be a Matching Problem, Not a Personal One

The finding

If you've tried a GLP-1 drug and it barely moved the needle while a friend on the same medication lost 20% of her body weight, new research out of the Mayo Clinic suggests that difference might not be about willpower, diet, or dose. It might be about which biological subtype of obesity you actually have.

Researchers led by gastroenterologist Andres Acosta studied 483 adults with obesity and identified three distinct biological patterns behind the condition. About one in four participants fit what the team calls a "hungry gut" phenotype: normal portion sizes but more frequent snacking, faster stomach emptying, lower natural levels of appetite-regulating hormones, and greater hunger after meals. People with this phenotype lost an average of 21.5% of their body weight on tirzepatide over six months, nearly double the 11.7% average in the other groups.

What they found

The hungry-gut finding isn't the only place this pattern is showing up. Two additional trials, both published this year, looked at what semaglutide does outside of weight and blood sugar:

• Liver scarring. A 698-person international trial in adults with advanced fatty liver disease (MASH), including some with early-stage cirrhosis, found that semaglutide on its own produced a statistically significant improvement in liver scarring, without worsening liver inflammation, even in patients with the most advanced disease.
• Biological aging markers. A smaller trial of 108 adults with HIV-associated fat redistribution found that semaglutide slowed the pace of biological aging, measured through DNA methylation "clocks," by about 9% on one of the clocks used, over 32 weeks compared to placebo.

What the data cannot say

Here's where it's worth slowing down. The hungry-gut phenotype work is a real, mechanistically grounded finding, but it comes from analyzing an existing study group after the fact, not from a trial that assigned people to treatment based on their phenotype and then measured the result. Acosta's own team says as much: prospective studies are needed before this becomes something a doctor can actually use to pick your medication. Call it an important early step, not a ready-to-use test.

The liver and aging findings sit on firmer ground methodologically, both were randomized, placebo-controlled trials, so the effects seen are real treatment effects, not just an association in the data. But firmer methodology doesn't mean settled science. The liver trial is the first of its kind and needs replication, particularly in patients with cirrhosis. The aging study's own lead author was careful to say semaglutide isn't reversing aging or making anyone younger, only that it may slow some of the biological processes tied to it, in a specific population (adults with HIV) that doesn't necessarily generalize to everyone.

Why this matters for women

If you've been on a GLP-1 and felt like it "should" have worked better, or you've watched someone else's results outpace yours on the same drug and dose, this research offers a real, biological reason that isn't about anything you did or didn't do. Obesity researchers are increasingly describing obesity as several different conditions that look similar from the outside, and matching the right drug to the right underlying biology is where the field seems to be heading.

That reframe matters, but it isn't a reason to switch medications on your own or assume you know your phenotype from how you feel. It's a reason to bring these findings to a conversation with a doctor who can weigh them against your actual history and labs.

What's next

Acosta's group is calling for prospective trials that assign treatment by phenotype rather than identifying it after the fact, the study design that would actually prove personalized matching improves outcomes. The liver researchers want larger trials focused specifically on patients with cirrhosis. And the aging researchers want to compare how different GLP-1 drugs affect biological aging markers across a wider range of patients, not just those with HIV. All three research threads point toward the same next step: bigger, purpose-built trials, not another look back at existing data.